A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genentech
  • Most Recent Events

    • 18 Apr 2018 Results assessing association between baseline relative lymphocyte counts and improvement in clinical outcome (n=426) presented at the 109th Annual Meeting of the American Association for Cancer Research.
    • 10 Feb 2018 Results from metastatic castration-resistant prostate cancer cohort (n=15; data cutoff: December 31, 2016) presented at the 2018 Genitourinary Cancers Symposium
    • 17 Jan 2018 Results of pooled data from four trials (BIRCH, POPLAR, IMvigor210 and PCD4989g), were published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top